Boehringer Ingelheim

Topics • Technology

Boehringer, Vitae ink $242 Million Alzheimer’s Deal

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

German Biotech Days 2026: Biotechnology as The Key to Industrial Competitiveness

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Interview

Interconnected Global Chemicals Logistics

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Oracle Germany

PP Consulting

SchüllerConsulting

CHEManager International c/o Wiley-VCH GmbH

QUANTRO Therapeutics GmbH

GlobalData

Boehringer Ingelheim

JMP Statistical Discovery / SAS Institute GmbH

Frost & Sullivan

Bayer AG

DCAT - Drug, Chemical & Associated Technologies Association

Thomson Reuters

C² PHARMA

BearingPoint GmbH

LISA Life Science Austria

ACIB Austrian Centre of Industrial Biotechnology

Boehringer Ingelheim

GlaxoSmithKline Unit Joins Patent Pool for AIDS Drugs

Boehringer Ingelheim Ohio Subsidiary Enters Consent Decree

Global Meets Local in Austria

Eli Lilly Banks on Cost Controls for Higher 2013 Profit

Drugmaker Boehringer Settles Marketing Claim for $95 Million

Maturing Belgian Biotechs Outshine European Peers

Stick to Your Strengths with Biosimilars

Thriving Generics

U.S. Medicine Spending Rose to $320 Billion Last Year

Bayer Sees Healthcare Business Driving Growth

Peter Pollak on the World of Fine Chemicals

Innovation Expected from API Manufacturers

Amylin Sues Lilly over Diabetes Partnership

Merck, Sanofi Animal Health JV to Close Later Than Expected

Novartis CEO Joe Jimenez: Animal Health Acquisition Makes Sense

Oracle’s Agile PLM Reorganizes Pharma, From Lab to Launch

Amgen To Sell California Drug Plant To Boehringer

Eli Lilly, Boehringer Ingelheim in Drug-Development Alliance

Fresenius Could Be in the Mood for Acquisitions

Abbott to Pay $121.5 Million in False Claims Settlement

Live And Learn

Pfizer Selling China Swine Vaccine Unit to Harbin Pharma

Pfizer Exec Jumps Ship to Head AstraZeneca's R&D

Cost, Quality And Reliability

Bayer Still Out To Buy, Not Sell, Vet Businesses

Boehringer to Buy Rest of Japan's SSP

Drugmaker Boehringer Ingelheim Not For Sale

Boehringer, Vitae ink $242 Million Alzheimer’s Deal

Top-Feature

Upcoming Virtual Events

German Biotech Days 2026: Biotechnology as The Key to Industrial Competitiveness

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Interview

Driving Transformation

Boehringer Ingelheim

Top-Feature

Upcoming Virtual Events

German Biotech Days 2026: Biotechnology as The Key to Industrial Competitiveness

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Interview

Newsletter & e-edition